1-[2-(1-Acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-4-(3,4-dichlorophenyl)piperidine | 439933-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[2-(1-Acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-4-(3,4-dichlorophenyl)piperidine
• 英文别名: 1-[3-[2-[4-(3,4-Dichlorophenyl)piperidin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone
• CAS: 439933-88-7
• 化学式: C₂₃H₂₆Cl₂N₂O
• 分子量: 417.378
• InChiKey: VIHFYGJNDLKWET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Indoline derivatives
  申请人：H. Lundbeck A/S

  公开号：US20040044007A1

  公开（公告）日：2004-03-04

  The present invention relates to methods of treating psychiatric or neurologic disorders, in particular psychoses, by administration of a compound formula of (I) 1 wherein R 1 is acyl, thioacyl, trifluoromethylsulfonyl or R 1 is a group R 12 SO 2 —, R 12 OCO— or R 12 SCO— wherein R 12 is C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl or aryl, or R 1 is a group R 13 R 14 NCO, R 13 R 14 NCS—, wherein R 13 and R 14 are independently hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl or aryl, or R 13 and R 14 together with the N-atom to which they are linked form a pyrrolidinyl, piperidinyl or perhydroazepin group; n is 1-6; X is C, CH or N, and the dotted line emanating from X indicates a bond when X is C and no bond when X is N or CH; R′, R″ and R 2 are independently selected from hydrogen and C 1-6 -alkyl; R 3 -R 11 are independently selected from hydrogen, halogen, cyano, nitro, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-8 -cycloalkyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, amino, C 1-6 -alkylamino, di-(C 1-6 -alkyl)amino, C 1-6 -alkylcarbonyl, aminocarbonyl, C 1-6 -alkylaminocarbonyl, di-(C 1-6 -alkyl)aminocarbonyl, C 1-6 -alkoxy, C 1-6 -alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and C 1-6 -alkylsulfonyl; or a pharmaceutically acceptable acid addition salt thereof.

  本发明涉及通过给予(I)1式化合物的配方治疗精神或神经疾病，特别是精神病，其中R1为酰基，硫酰基，三氟甲基磺酰基，或R1为R12SO2—，R12OCO—或R12SCO—的基团，其中R12为C1-6烷基，C2-6烯基，C2-6炔基，C3-8环烷基，C3-8环烷基-C1-6烷基或芳基，或R1为R13R14NCO，R13R14NCS—的基团，其中R13和R14分别为氢，C1-6烷基，C2-6烯基，C2-6炔基，C3-8环烷基，C3-8环烷基-C1-6烷基或芳基，或R13和R14与它们连接的N原子一起形成吡咯烷基，哌啶基或过氢杂环庚烷基；n为1-6；X为C，CH或N，从X发出的点线表示当X为C时为一条键，当X为N或CH时为无键；R′，R″和R2独立选择自氢和C1-6烷基；R3-R11独立选择自氢，卤素，氰基，硝基，C1-6烷基，C2-6烯基，C2-6炔基，C3-8环烷基，C3-8环烷基-C1-6烷基，氨基，C1-6烷基氨基，二-(C1-6烷基)氨基，C1-6烷基羰基，氨基羰基，C1-6烷基氨基羰基，二-(C1-6烷基)氨基羰基，C1-6烷氧基，C1-6烷基硫基，羟基，三氟甲基，三氟甲基磺酰基和C1-6烷基磺酰基；或其药学上可接受的酸盐。
• 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS
  申请人：H. Lundbeck A/S

  公开号：EP1345921A1

  公开（公告）日：2003-09-24
• [EN] 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS<br/>[FR] DERIVES DE 3-INDOLINE UTILES DANS LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES ET NEUROLOGIQUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2002051833A1

  公开（公告）日：2002-07-04

  The present invention relates to the use of a compound having the general formula wherein R1 is acyl, thioacyl, trifluoromethylsulfonyl or R1 is a group R12SO2-, R12OCO- or R12SCO- wherein R12 is C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl or aryl, or R1 is a group R13R14NCO,- R13R14NCS-, wherein R13 and R14 are independently hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl or aryl, or R13 and R14 together with the N-atom to which they are linked form a pyrrolidinyl, piperidinyl or perhydroazepin group; n is 1-6;X is C, CH or N, and the dotted line emanating from X indicates a bond when X is C and no bond when X is N or CH;R', R'' and R2 are independently selected from hydrogen and C1-6-alkyl;R3-R11 are independently selected from hydrogen, halogen, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, amino, C1-6-alkylamino, di-(C1-6-alkyl)amino, C1-6-alkylcarbonyl, aminocarbonyl, C1-6-alkylaminocarbonyl, di-(C1-6-alkyl)aminocarbonyl, C1-6-alkoxy, C1-6-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and C1-6-alkylsulfonyl; or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament useful in the treatment of psychiatric and neurologic disorders, in particular psychoses.